EP0369686A1 — Hydrates of beta-lactam antibiotic
Assigned to Eli Lilly and Co · Expires 1990-05-23 · 36y expired
What this patent protects
The crystalline dihydrate and trihydrate forms of the antibiotic 7β-[2′-(R)-2′-phenyl-2′-aminoacetamido]-3-chloro-3-(1-carbadethiacephem)-4-carboxylic acid ("LY163892") are described. These hydrates are antibiotics in their own right, and are valuable intermediates to t…
USPTO Abstract
The crystalline dihydrate and trihydrate forms of the antibiotic 7β-[2′-(R)-2′-phenyl-2′-aminoacetamido]-3-chloro-3-(1-carbadethiacephem)-4-carboxylic acid ("LY163892") are described. These hydrates are antibiotics in their own right, and are valuable intermediates to the corresponding monohydrate form of LY163892.
Drugs covered by this patent
- Zetia (EZETIMIBE) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.